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Background: Although a decrease in serum potassium level has been suggested to be a fairly common
observation in acute coronary syndrome (ACS), there have so far been no definitive reports directly demonstrating
the transient potassium decrease (the potassium dip) during ischemic attack of ACS compared to stable phase in
individual patients. To understand the pathophysiological significance of the potassium dip, we examined the
changes in serum potassium level throughout ischemic attack and evaluated the clinical factors affecting it.
Methods: The degree of the potassium dip during ischemic attack (as indicated by ΔK, ΔK = K at discharge − K on
admission) was examined in 311 consecutive patients with ACS who required urgent hospitalization in our
institution.
Results: Serum potassium level during ischemic attack was significantly decreased compared to that during stable
phase (P < 0.001). Multiple regression analysis revealed that plasma glucose level during attack was the sole factor
which was positively correlated with ΔK (P < 0.01), while HbA1c level was negatively correlated (P < 0.05). The
medication profiles and renal function had no impact on ΔK. A longer hospitalization period, higher incidence of
myocardial infarction and higher peak creatine kinase level were observed in patients with a larger ΔK.
Conclusions: We have clearly demonstrated that there is a transient decrease in serum potassium level during
ischemic attack of ACS compared to stable phase. The degree of the potassium dip was tightly correlated with
glucose level, which overwhelmed the diabetic condition, and it also indicates the disease severity. The present
study therefore promotes awareness of the significance of monitoring potassium level in parallel with glucose level
in patients with ACS.
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A decrease in serum potassium (K) level has been sug-
gested to be a fairly common observation in patients
with acute coronary syndrome (ACS) [1-4], which has
been shown to increase the risk of cardiac events, in-
cluding lethal ventricular arrhythmias [5-7]. In addition,* Correspondence: tnagoshi@jikei.ac.jp
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reproduction in any medium, provided the ora decrease in K level generally induces vasoconstriction
[8], which leads to further ischemia, thereby producing a
vicious cycle. The optimal range of K level in ACS has
been recently discussed and reviewed [9], and the im-
portance of potassium homeostasis during ischemic at-
tack was thus clarified. However, little is known about
the pathophysiological significance of potassium kinetics
during ACS attack. Moreover, there have so far been few
studies directly demonstrating the transient relative de-
crease in K level during ischemic attack compared to
stable phase in individual patients (rather than itsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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K concentration on admission was around 4.0 mmol/L
in all of the previous reports, which is not technically
defined as hypokalemia. To see this transient K decrease,
“the potassium dip,” during ischemic attack, it would be
necessary to evaluate the fluctuation of K level in indivi-
duals by comparing the data during an attack to those
during stable phase. We hypothesized that the degree of
the decrease in serum K level may indicate the disease
severity of ACS. To understand the pathophysiological
significance of the potassium dip in ACS and to ensure
that patients have an optimal serum K level during the
acute phase of ischemic attack, we herein examined the
changes in K level throughout ischemic attack and eval-
uated the clinical factors affecting it.
Methods
Study patients
The study protocol was approved by the ethics commit-
tee of The Jikei University School of Medicine (21-027
(5605)).
Patients with ACS who required emergency admission
to The Jikei University Hospital from January 2006 to
December 2011 were included in this study. ACS was
defined as the presence of myocardial infarction (MI) or
unstable angina pectoris, as described previously [10].
Briefly, the diagnosis of MI required the presence of any
two of the following three criteria: (1) a history of cardiac
chest pain lasting at least 30 minutes; (2) typical electro-
cardiographic changes (i.e. ≥ 0.1 mV ST elevation in at
least one standard lead or two precordial leads, ≥ 0.1 mV
ST depression in at least two leads, abnormal Q waves, or
T-wave inversions in at least two leads); (3) an increase in
serum creatine kinase (CK) level to more than twice the
upper limit of the normal range. All patients with MI were
admitted to the hospital within 1 week of the onset.
Unstable angina pectoris was diagnosed when patients
fulfilled the criteria for the Braunwald clinical classifica-
tion without an increase in serum CK level [11]. Patients
were excluded if they were receiving or beginning to
receive dialysis, were taking potassium controlling agents,
or died from any cause during hospitalization. Based on
these selection criteria, 311 consecutive patients, including
188 with MI, were enrolled.
Data collection
The baseline characteristics, including the clinical para-
meters and the biochemical data, were collected retro-
spectively from the hospital medical records. The serum
K level on admission was defined as K during ischemic
attack, and the serum K level at the time of discharge
was defined as K during stable phase. The degree of the
potassium dip during ischemic attack (as indicated by
ΔK) was calculated from the difference between K atdischarge and K on admission:
ΔK ¼ K at discharge K on admission
In other words, a larger ΔK indicates a greater de-
crease in serum K level during ischemic attack in com-
parison to K level during the stable phase.
The serum K level before admission was available in
85 patients that had incidentally undergone blood tests
within six months before the ischemic attack. All other
biochemical data, including plasma glucose level, were
measured at the time of admission, except for peak CK
level. Diabetes mellitus (DM), hypertension, and dyslipi-
demia were defined as described previously [10,12]. The
estimated glomerular filtration rate (eGFR) was calcu-
lated as described previously [12]. The hemodynamic
parameters, including left ventricular ejection fraction
(LVEF), were measured on the day of admission.
Definitions of the medication profiles
To evaluate the involvement of renin-angiotensin-
aldosterone system inhibitors (RAAS-I) and diuretics,
we examined the influence of the changes in each medi-
cation profile as follows: “no change” indicates that
those medications were or were not taken both on
admission and at the time of discharge; “newly adminis-
tered” indicates that those medications were not taken
on admission but were introduced during hospitalization;
“discontinuation” indicates that those medications were
taken on admission but were discontinued during
hospitalization.
Statistical analysis
Continuous variables were expressed as the means ± SD.
To compare the serum K level between groups, the stat-
istical analyses were performed using one way repeated
measure analysis of variance, followed by a Bonferroni
multiple comparison correction for three phases and
paired sample t-test for two groups. The statistical ana-
lyses were performed using one way analysis of variance
(ANOVA) followed by Scheffe’s test to assess the influ-
ence of β-blocker use on admission and the changes in
the medication profiles of RAAS-I and diuretics on ΔK.
To assess the determinants of ΔK, multiple regression
analyses were performed after simple regression analyses
were performed. The patients’ age, blood pressure, B-
type natriuretic peptide (BNP), body mass index (BMI),
glycohemoglobin (HbA1c), eGFR, glucose, K level on ad-
mission, LVEF, change in medication profile of RAAS–I
and diuretics, and use of β-blockers on admission were
included as variables. In the multiple regression analysis,
indicator variables were employed as follows; one indica-
tor variable coded as 0/1 for variable with two categories
(use of β-blockers on admission) and two indicator
Sekiyama et al. Cardiovascular Diabetology 2013, 12:4 Page 3 of 7
http://www.cardiab.com/content/12/1/4variables for variables with three categories (changes in
medication profiles of RAAS-I and diuretics) were
generated. The regression coefficient of each indicator
variable indicates the effect of that category in compari-
son to “no change” in each medication profile (as a basic
category). All patients were divided into two groups
based on the median value of ΔK and serum K on
admission, to investigate the association of ΔK and serum
K on admission with the disease severity and clinical
course. Continuous variables were evaluated by the Welch
test for unequal variances, Student’s t-test for equal
variances and the Chi-square test for categorical variables.
P < 0.05 was considered to be statistically significant. All
data were statistically analyzed using the SPSS software
package, version 11.5 (SPSS Inc., Chicago, IL).
Results
The baseline clinical characteristics of the 311 patients
are shown in Table 1. The mean serum K level was
4.1 ± 0.4 mmol/L during ischemic attack (on admission)
and 4.4 ± 0.4 mmol/L during stable phase (at discharge).
K on admission was significantly decreased compared
to K at discharge (Figure 1A, P < 0.001) and K beforeTable 1 Baseline characteristics (n = 311)
Age, years 63 ± 12
Male, gender (%) 260 (83.6)
Height, cm 167 ± 34.2
Weight, kg 66.4 ± 12.5
BMI, kg/m2 24.1 ± 3.9
BP, mmHg
Systolic 137 ± 27
Diastolic 78 ± 17
Mean 98 ± 19
K on admission, mmol/L 4.1 ± 0.4
K at discharge, mmol/L 4.4 ± 0.4
eGFR, mL/min/1.73m2 71.1 ± 22.6
Cr, mg/dL 0.9 ± 0.3
HbA1c, % 6.0 ± 1.2
Glucose, mg/dL 155 ± 68
BNP, pg/mL 144 ± 317
LVEF, % 54 ± 10.9
Time of hospital stay, days 12.3 ± 9.9
Myocardial infarction (%) 188 (60.5)
Unstable angina (%) 123 (39.5)
Diabetes mellitus (%) 122 (39.2)
Hypertension (%) 212 (68.2)
BMI: body mass index, BP: blood pressure, K: potassium.
Cr: creatinine, eGFR: estimated glomerular filtration rate.
BNP: B-type natriuretic peptide.
LVEF: left ventricular ejection fraction.admission (Figure 1B, P < 0.025). The mean plasma
glucose level on admission was 155 ± 68 mg/dL and the
mean HbA1c was 6.0 ± 1.2% (Table 1). A total of 60.5%
of the patients were diagnosed with MI and 39.2% were
diagnosed with type 2 DM.
Of the 311 patients, 125 (40.2%) had taken one or
more RAAS-I and/or diuretics on admission and 260
(83.6%) had taken these agents at the time of discharge
(Additional file 1). Forty-nine patients (15.6%) had
taken β-blockers on admission (β1 selective β-blockers:
26 patients; non-selective β-blocker: 23 patients) and
131 (42.1%, β1 selective β-blockers: 21; non-selective
β-blocker: 110) had taken β-blockers at the time of
discharge.
We performed a simple regression analysis to evaluate
the determinants of ΔK (Table 2). Plasma glucose level
during ischemic attack (on admission) showed a signifi-
cantly positive correlation with ΔK (Figure 2A,
P = 0.026). On the other hand, there was a negative cor-
relation between ΔK and K on admission (Figure 2B,
P < 0.001). ΔK was not associated with HbA1c and eGFR
on admission.
To evaluate the involvement of RAAS-I and diuretics,
we examined the influence of the changes in each medi-
cation profile on ΔK. The group of RAAS-I “newly
administered” during hospitalization showed a signifi-
cantly larger ΔK in comparison to the “no change” group
(Figure 3A, P < 0.04). The other variations of medication
profiles including RAAS-I discontinuation and diuretics
with any changes had no impact on ΔK (Figure 3A and
3B). We next examined the influence of each β-blocker
use at the time of admission on ΔK. The subjects with
non-selective β-blocker use on admission, but not those
with β1 selective β-blockers use, exhibited significantly
smaller ΔK values compared to the subjects who did not
take any β-blockers on admission (Figure 4, P < 0.05).
To assess the independent determinants of ΔK, a mul-
tiple regression analysis was performed (Table 3). The
medication profile of RAAS-I and the use of β-blockers
on admission no longer had any impact on ΔK, although
the profile of non-selective β-blocker use showed a ten-
dency toward negative correlation that did not achieve
statistical significance. Intriguingly, the plasma glucose
level during ischemic attack (on admission) was found
to be the only independent factor positively correlated
with ΔK (P = 0.005). In contrast, the independent factors
negatively correlated with ΔK were HbA1c (P = 0.04)
and K on admission (P < 0.001). Meanwhile, there was a
significant positive correlation between plasma glucose
level on admission and HbA1c (P < 0.001 in a linear
regression analysis, data not shown).
We investigated the association of ΔK with the disease
severity and clinical course to evaluate the clinical impli-
cations of ΔK during ischemic attack of ACS. A longer
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A Bn=311 n=85
Figure 1 The time course of the serum potassium concentration (K) profile. A. The average ± SD of K level in the total study patients
(n = 311) on admission (during ischemic attack) and at discharge (during stable phase) (paired t-test, **P < 0.001). B. The K level in the 85 patients
for whom the data before admission were available (**P < 0.001 and *P < 0.025 by one way repeated measure analysis of variance, followed by a
Bonferroni multiple comparison correction for three phases). NS; not significant.
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MI and higher peak CK level were observed in patients
with a larger ΔK (Table 4). It has been reported that a
decreased serum K level per se increases cardiovascular
risks [9,13,14]. Therefore, we also examined the impact
of serum K level at the time of admission on the clinical
consequences and found a higher incidence of MI and
higher peak CK level in the patients with lower K level
(K < 4.1) on admission (Table 5).
Discussion
In the present study, we found that in ACS patients,
serum K level is significantly decreased during ischemic
attack compared to the stable phase in individual sub-
jects. We examined multiple clinical factors affecting
the degree of the potassium dip (as indicated by ΔK),
and found that the plasma glucose level during ischemic
attack was the sole factor which was positively corre-
lated with ΔK. In contrast, HbA1c level was negatively
correlated with ΔK.Table 2 The results of a simple regression analysis of ΔK (n =
Explanatory variables Regression coefficients Standard err
K on admission −0.815 0.048







Blood pressure (mean) 0.002 0.002
ΔK = K at discharge − K on admission.
K: potassium, eGFR: estimated glomerular filtration rate, BNP: B-type natriuretic pep
pressure.There was no link between the medication profiles
and ΔK, such as the use of ACE-inhibitors, ARBs, MR-
inhibitors and diuretics, after adjusting for any potential
confounders of ΔK, even in patients who had been on
these medications before admission (Table 3). Moreover,
the renal function, as indicated by eGFR did not affect
the potassium dip, suggesting that the potassium kinetics
during ischemic attack are not simply regulated by renal
elimination.
Although a couple of potential mechanisms for this K
decrease have been proposed [1-4,14], the precise
mechanisms remain to be elucidated. Meanwhile, we
have previously reported that K level decreases with the
severity of heart failure if renal function is preserved
[15].
It is possible that insulin stimulates an intrace-
llular K shift into the cardiac and skeletal muscles via
Na+/K+ATPase activation, leading to the decrease in
serum K level [16-19]. In the present study, plasma glu-
cose level during attack was positively correlated with311)




































Figure 2 The results of the simple regression analyses. The simple regression analyses between plasma glucose level on admission (during
ischemic attack) and ΔK (A), between serum K level on admission (during ischemic attack) and ΔK (B) are shown. ΔK = K at discharge -
K on admission.
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would also be positively correlated with ΔK. However,
we found that HbA1c was not correlated with ΔK in the
simple regression analysis and was actually negatively
correlated with ΔK after adjusting for any potential con-
founders. Although this negative correlation is relatively
weak, one can still say that an elevated glucose level
during attack is tightly associated with an enhanced ΔK,
regardless of the severity of diabetic condition. These
findings suggest that insulin resistance may have had a
role in attenuating the potassium dip, and that there are
other serum K lowering systems that may overwhelm
the effects of insulin resistance, as discussed below.
Further investigations are required to fully demonstrate
that the tight correlation between glucose and ΔK over-
whelms insulin resistance using other parameters, such
as homeostasis model assessment ratio (HOMA-R),










Figure 3 The comparison of ΔK among the changes in the medicatio
profiles of rennin-angiotensin-aldosterone system inhibitors (RAAS-I) (A) an
indicated medication profiles were described in the Methods section. *P < 0
subjects. NS; not significant.The systemic sympathetic nerve system can be acti-
vated by ischemic stress, and elevated catecholamines
stimulate Na+/K+ATPase primarily via β2-adrenergic
receptor [1-4,20,21]. In fact, in the present study, non-
selective β-blocker use on admission, but not β1 select-
ive β-blocker use, reduced ΔK in the one-way ANOVA
(Figure 4), although the multiple regression analyses
showed only a tendency toward a negative correlation
between non-selective β-blocker use and ΔK that did
not achieve statistical significance (Table 3). These
data indicate that catecholaminergic effects via β2-
adrenergic receptor would be partially involved, but
that they cannot explain the entire extent of the potas-
sium dip.
Sodium-proton exchanger (NHE) also stimulates
Na+/K+ATPase [16]. Although insulin is one of the
NHE activators [22,23], diabetic condition (namely,
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d diuretics (B) in all patients (n = 311) are shown. The definitions of the









Figure 4 A comparison of ΔK among the medication profiles of
β-blockers on admission. A comparison of ΔK among the
medication profiles of β-blockers(−) indicating the subjects who did
not take any β-blockers on admission (n = 262), those with β1
selective β-blockers use (n = 26) and those with non-selective β-
blocker use (n = 23) on admission is shown. *P < 0.05 by one way
analysis of variance, followed by Scheffe’s test for three subjects. NS;
not significant.








10.5 ± 10.8 13.8 ± 8.9 P = 0.0039
Myocardial Infarction 59 (43.4%) 124 (70.9%) P < 0.001
Peak Creatine Kinase (U/L) 1010.0 ± 1540.3 2004.1 ± 2329.0 P < 0.001
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intracellular acidification and some neurohumoral regula-
tors, including the renin-angiotensin-aldosterone system
are directly involved in the activation of NHE under the
presence of insulin resistance [24,25].Table 3 The results of a multiple regression analysis of









K on admission −0.77 0.049 −0.659 <0.001
Glucose on admission 0.001 0.0005 0.177 0.005




0.047 0.079 0.025 0.551
(non-selective) −0.161 0.084 −0.8 0.058
RAAS-I newly
administered
0.05 0.047 0.048 0.286
Discontinued 0.04 0.119 0.014 0.736
Diuretics newly
administered
0.1 0.085 0.052 0.24
Discontinued 0.114 0.143 0.032 0.426
No significant variables (other than the medication profiles): BMI, Age, BP,
eGFR, LVEF, BNP.
Dependent variable: ΔK.
Explanatory variables: BMI, Glucose, Age, BP, K on admission, HbA1c, eGFR,
RASS-I or diuretics newly administered,
RAAS-I or diuretics discontinued, LVEF, BNP, use of β-blocker on admission.
K: potassium.One can infer that the intracellular components, in-
cluding potassium, leak out when cardiomyocytes are
damaged by ischemic attacks, thus leading to an increase
in serum K level during attack (namely, ΔK reduction)
just like cardiac enzymes, such as CK(−MB). However,
the present study demonstrated that a higher peak CK
level was observed in patients with a larger ΔK and a
lower K (K < 4.1) on admission (Table 4). Moreover, the
subanalysis with MI subjects (n = 188) in a multiple
regression analysis demonstrated that ΔK was not sig-
nificantly correlated with peak CK level (if anything, ΔK
was actually found to be positively correlated with peak
CK level in a simple regression analysis, data not shown,
n = 188, P = 0.002), thus suggesting that ΔK reflects the
severity of ischemic stress rather than the extent of
cellular injury.
In accord with previous reports demonstrating that a
decrease in serum K level during the acute phase of ACS
increases the risk of cardiovascular events [1,3-7], we
found in the present study that more severe ischemia
was observed in patients with a lower K level on admis-
sion (Table 5). Moreover, the present study revealed that
a lower serum K level on admission was associated with
a larger ΔK (Figure 2b, Tables 2 and 3). Considering that
the patients who presented with lower K level during is-
chemic attack did not necessarily continue to exhibit
relatively low K concentration during stable phase, these
data indicate that lower K subjects are more susceptible
to larger potassium dip, thus suggesting that serum K
level on admission per se reflects disease severity.
The main limitation of this study was that we did not
measure the hormonal changes (i.e. serum concentrations
of catecholamine, insulin, aldosterone, ACTH, cortisol etc.)
or the urinary potassium concentration during attacks.
Therefore, the mechanisms described above still remainTable 5 The impact of K level on admission on disease





Time of hospital stay (days) 11.6 ± 9.5 13.2 ± 10.3 NS
Myocardial Infarction 88 (52.1%) 95 (66.9%) P = 0.011
Peak Creatine Kinase (U/L) 1343.5 ± 1853.7 1838.3 ± 2296.3 P = 0.04
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termine the K and glucose concentrations in the coronary
sinus, so that the local potassium kinetics in the ischemic
heart, where glucose becomes an important preferential
substrate for metabolism [26,27], could be evaluated.Conclusions
The present study clearly showed a transient decrease
to exist in serum K level during ischemic attack of ACS.
The degree of the potassium dip was tightly correlated with
glucose level, which overwhelmed the diabetic condition
and the variations in the medication profiles. The study
suggests that the potassium dip indicates the severity of
acute ischemic stress, thus promoting awareness of the
significance of monitoring K level in parallel with glucose
level in patients with ACS, especially in severe cases.Additional file
Additional file 1: Medication profile. ACE-I: angiotensin-converting-
enzyme inhibitor, ARB: angiotensin-receptor-blocker,
RAAS-I: renin-angiotensin-aldosterone system inhibitors.
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